Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/34656
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kocatürk, Emek | - |
dc.contributor.author | Pırıl, Etikan | - |
dc.contributor.author | Oktay, Taşkapan | - |
dc.contributor.author | Nilgün, Atakan | - |
dc.contributor.author | Teoman, Erdem | - |
dc.contributor.author | Serap, Utaş | - |
dc.contributor.author | Ekin, Savk | - |
dc.contributor.author | Rafet, Koca | - |
dc.contributor.author | Şebnem, Aktan | - |
dc.date.accessioned | 2023-10-30T07:48:58Z | - |
dc.date.available | 2023-10-30T07:48:58Z | - |
dc.date.issued | 2017-09-09 | - |
dc.identifier.citation | Kocatürk, E. vd. (2018). ''Turkish dermatologists' approach for chronic spontaneous urticaria: A questionnaire based study''. Dermatologica Sinica, 36(2), 70-74. | en_US |
dc.identifier.issn | 1027-8117 | - |
dc.identifier.issn | 2223-330X | - |
dc.identifier.uri | https://doi.org/10.1016/j.dsi.2017.09.002 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S1027811717300903 | - |
dc.identifier.uri | http://hdl.handle.net/11452/34656 | - |
dc.description.abstract | Background/Objectives: Chronic spontaneous urticaria (CSU) is a common skin disorder which represents a challenge both for the patients and physicians. Guidelines and treatment algorithms have been created to help physicians to ease management. Our aim was to determine Turkish dermatologists' approach to CSU with regard to treatment, search for causative factors and use of instruments to assess the quality of life and severity of the disease. Methods: This was a cross-sectional methodological study which was performed by delivery of a questionnaire including ten questions about the management of CSU. Results: Analyses of 314 questionnaires revealed that the most common first-line treatments were non-sedating antihistamines in standard doses (65.6%), while second-line treatment was updosing antihistamines (59.9%) followed by addition of sedative-antihistamines (26.4%) and systemic steroids (19.1%). Third-line treatment option was omalizumab in 35% followed by systemic steroids. Twenty-two percent of the dermatologists referred the patients to a center experienced in urticaria. Most of them were performing laboratory testing for underlying causes including thyroid function tests, C-reactive protein, thyroid auto-antibodies, stool analyses, infection markers. Urticaria activity score and chronic urticaria quality of life questionnaire were used by 30 and 13%, respectively, while 56% were using none of the instruments. Conclusion: Our study showed that the therapeutic management of Turkish dermatologists was parallel to the European Urticaria Guidelines. The high utility of omalizumab as a third line regimen improved patient care. Nevertheless there is a need for centers experienced in urticaria to refer anti-histamineresistant patients where third-line treatment options can not be implemented. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wolters Luver Medknow Publications | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Atıf Gayri Ticari Türetilemez 4.0 Uluslararası | tr_TR |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Dermatology | en_US |
dc.subject | Urticaria | en_US |
dc.subject | Dermatologists | en_US |
dc.subject | Therapeutics | en_US |
dc.subject | Diagnosis | en_US |
dc.subject | Guideline | en_US |
dc.subject | Chronic idiopathic urticaria | en_US |
dc.subject | Management | en_US |
dc.subject | Diagnosis | en_US |
dc.subject | Omalizumab | en_US |
dc.subject | Guideline | en_US |
dc.subject | Life | en_US |
dc.title | Turkish dermatologists' approach for chronic spontaneous urticaria: A questionnaire based study | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000433284500002 | tr_TR |
dc.identifier.scopus | 2-s2.0-85031672386 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Dermatoloji ve Zührevi Hastalıklar Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0002-0144-3263 | tr_TR |
dc.identifier.startpage | 70 | tr_TR |
dc.identifier.endpage | 74 | tr_TR |
dc.identifier.volume | 36 | tr_TR |
dc.identifier.issue | 2 | tr_TR |
dc.relation.journal | Dermatologica Sinica | en_US |
dc.contributor.buuauthor | Emel, Bülbül Başkan | - |
dc.contributor.researcherid | AAH-1388-2021 | tr_TR |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.subject.wos | Dermatology | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.wos.quartile | Q4 | en_US |
dc.contributor.scopusid | 57196063450 | tr_TR |
dc.subject.scopus | Omalizumab; Urticaria; Non-Sedating Histamine H1 Antagonists | en_US |
dc.subject.emtree | Antihistaminic agent | en_US |
dc.subject.emtree | C reactive protein | en_US |
dc.subject.emtree | Omalizumab | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Chronic urticaria | en_US |
dc.subject.emtree | Cross-sectional study | en_US |
dc.subject.emtree | Dermatologist | en_US |
dc.subject.emtree | Disease severity | en_US |
dc.subject.emtree | Health care delivery | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Laboratory test | en_US |
dc.subject.emtree | Practice guideline | en_US |
dc.subject.emtree | Quality of life | en_US |
dc.subject.emtree | Questionnaire | en_US |
dc.subject.emtree | Thyroid function test | en_US |
dc.subject.emtree | Treatment outcome | en_US |
Appears in Collections: | Scopus Web of Science |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Kocatürk_vd_2018.pdf | 185.94 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License